Company intelligence / Profile preview

Peking University V-Ming Biotech

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

PKU V-Ming is a leading investment holding company founded by Beijing Sinobioway Group, focused on capital appreciation and international investment banking for high-growth companies, particularly in the biomedicine sector. It is involved in consortiums for acquisitions, such as the proposed acquisition of Sinovac Biotech Ltd.

Industry: Investors

Partnerships

Shandong Sinobioway Biomedicine Co., Ltd.CICC Qianhai Development (Shenzhen) Fund Management Co., Ltd.Sinovac Biotech Ltd. (proposed acquisition consortium)

Beyond the preview

Go deeper on Peking University V-Ming Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peking University V-Ming Biotech.

Explore the full profile